

Travel Fellowship Awardees

Name	Suffix	Institute or Affiliation:	Abstract Titles for selected abstracts
Andi Cani	PhD	University of Michigan	Serial monitoring of circulating tumor cells and circulating tumor DNA in metastatic lobular breast cancer identifies intra-tumor heterogeneity and precision and immunology biomarkers of therapeutic importance
Annapurna Gupta	PhD	The Ohio State University	Downregulation of Arginosuccinate synthase 1 confers Tamoxifen Resistance in Invasive Lobular Breast Cancer
Esme Bullock		University of Edinburgh, UK	Cancer-associated fibroblast driven paracrine IL-6/STAT3 signalling promotes migration and dissemination of Invasive Lobular Carcinoma cells
Gitte Zels	MD	Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium	Overview of patients with invasive lobular breast carcinoma included in the post-mortem tissue donation program, UPTIDER
Higinio Dopeso	PhD	Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center	Genetic and Epigenetic Basis of Breast Invasive Lobular Carcinomas Lacking CDH1 Genetic Alterations
Jordan Swartz	BS	University of Colorado Anschutz Medical Campus	Efficacy of PARP inhibitor Talazoparib on ER+ ILC breast cancer models
Matteo Serra	MS	Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium	Spatially resolved analysis of tumor microenvironment revealed biologically driven subgroups with distinct clinical outcome in invasive lobular carcinoma
Rita Canas-Marques	MD	Champalimaud Foundation, Lisboa, Portugal	Aberrant E-cadherin (E-cad) Expression in Lobular Carcinoma in Situ (LCIS): A Comprehensive Evaluation of N-terminal, Extracellular, and C-terminal E-cadherin Domains
Sarah Nash	MBChB BSc	Institute of Cancer Research, London	Transcriptomic and immune heterogeneity underpin the biology of pleomorphic invasive lobular breast cancer
Sumayya Abdul Qadir	BS	University of Toronto	Developing and Characterizing a Model for Recurrent Invasive Lobular Breast Carcinoma with Nf1 and HER2/Neu Mutations